August 24, 2020 -- Moderna is in discussions with the European Commission to supply 80 million doses of messenger RNA (mRNA)-1273, Moderna's COVID-19 vaccine candidate, as part of the commission's goal to secure early access to safe and effective COVID-19 vaccines for Europe.
The potential agreement with the commission for 80 million doses also provides an option for European Union member states to purchase an additional 80 million doses for a total of up to 160 million doses. Discussions are underway to ensure that member states will have access to the vaccine.
The phase III study of mRNA-1273, a prefusion-stabilized spike protein mRNA vaccine against SARS-CoV-2, began on July 27 and is currently enrolling a target 30,000 participants by September.
Moderna is scaling up global manufacturing to be able to deliver approximately 500 million doses per year and possibly up to 1 billion doses per year beginning in 2021. In Europe, Moderna is partnering with Lonza in Switzerland and Rovi in Spain for manufacturing and fill-finish outside of the U.S.